Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies.
Overview
abstract
Myeloma patients progressing on BCMA-targeted therapy can maintain BCMA expression and still respond to different BCMA-targeted therapy. These observations suggest this patient population could be included in ongoing BCMA-targeted therapy trials.
